Clinical trials jobs provider Pfizer has highlighted positive results from a new study showing the potential benefits of its new Inspra drug in protecting high-risk individuals from the effects of heart disease.
Results from the pharmaceutical company's Emphasis-HF trial, which was showcased at the European Society of Cardiology Congress, revealed that the medication can reduce rates of cardiovascular death and heart failure when added to standard therapy.
Among the high-risk patients who could benefit from the use on Inspra are individuals over 75, left ventricular ejection or type 2 diabetes sufferers, and those affected by issues with their systolic blood pressure or estimated glomerular filtration rate.
Professor Bertram Pitt from the University of Michigan School of Medicine's cardiology division said: "The results reported today suggest that adding eplerenone to standard therapy can significantly reduce cardiovascular death and hospitalisation in these patients who are of particular concern to clinicians."
Earlier this month, the pharmaceutical company revealed that two of its newest cancer therapies, bosutinib and crizotinib, had been accepted for review by the European Medicine's Agency.